Photo: Amber Tong, Endpoints News
In a bid to get to Chinese patients faster, Shanghai's I-Mab plans $100M Nasdaq IPO
Aiming to be the next Chinese company to list on Nasdaq after Zai Lab’s debut two years ago, the Shanghai drug developer I-Mab is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
